Loading patent…
AssigneesDaiichi Sankyo Company, Limited, Daiichi Sankyo Europe GmbH, Amgen Inc.
InventorsMatthias Schneider, Sabine Blum, Renee Jeanne Mendell-Harary, Daniel J. Freeman, Robert Allen Beckman, Xiaoping Jin
Estimating the term…
The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.
A method of treating a human subject with a locally advanced or metastatic non-small cell lung cancer (NSCLC) that is characterized as having a high heregulin (HRG) expression at an mRNA level, comprising:
Dependencies are inferred from the claim text.